{"schema_version":"1.0","type":"article","title":"GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy","url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.md","lang":"en","date":"2026-06-30","publish_at":"2026-06-30T00:43:58.356Z","updated_at":"2026-06-30","category":"商業分析系列","topic":"商業分析系列","tags":["GSK","Nuvalent","Oncology","Lung cancer","ROS1","ALK","BD","M&A","Biotech investing","Big Pharma"],"summary":"GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.","key_points":[],"facts":[],"sections":["01 | GSK is buying two near-market lung-cancer entry points","02 | GSK sold oncology once. Now it is paying a higher price to return.","03 | The Miels playbook: large M&A, mid-sized acquisitions, and global BD","04 | The biggest risk: buying assets is not the same as selling drugs","05 | How Taiwan should read this deal: do not only look for the usual names","Conclusion | GSK has pushed real chips back onto the oncology table"],"references":[{"title":"[The Guardian: GSK to buy US cancer treatment firm Nuvalent in $10bn deal]","source":"","date":"","url":"https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels"},{"title":"[Investor's Business Daily: Nuvalent stock surges on GSK acquisition]","source":"","date":"","url":"https://www.investors.com/news/technology/nuvalent-stock-gsk-acquisition/"},{"title":"[MarketWatch: GSK announces its biggest purchase in eight years]","source":"","date":"","url":"https://www.marketwatch.com/story/gsk-just-announced-its-biggest-purchase-in-eight-years-to-rev-up-cancer-portfolio-it-had-previously-wound-down-a95e6065"},{"title":"[Barron's: Nuvalent stock jumps on GSK cancer deal]","source":"","date":"","url":"https://www.barrons.com/articles/nuvalent-stock-gsk-cancer-deal-89443e68"},{"title":"Company websites and public disclosures","source":"","date":"","url":""}],"images":[{"alt":"Figure 01: Two near-market lung-cancer entry points in ROS1 and ALK","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-01.png"},{"alt":"Figure 02: Why GSK returned to oncology after stepping away from the field","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-02.png"},{"alt":"Figure 03: The Miels playbook combines large M&A, mid-sized acquisitions, and global BD","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-03.png"},{"alt":"Figure 04: Buying assets is not the same as selling drugs","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-01.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-30）。GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy。https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-30-gsk-nuvalent-oncology-comeback.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}